Associated Papers
Overlap of familial Mediterranean fever and APLAID treated with anakinra: a case-based review.
Akoglu G et al.
Clinical Rheumatology, 2025
Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor.
Yang Z et al.
Arthritis & Rheumatology (hoboken, N.j.), 2024
Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL.
Brown J et al.
Research Square, 2024
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S et al.
Blood Advances, 2023
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
Lampson BL et al.
Expert Review of Hematology, 2018
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
Jones D et al.
Leukemia, 2017
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Burger JA et al.
Nature Communications, 2016
27199251 (PubMed )
Supplement: ncomms11589-s2.xlsx › MM_workingCopy-1.txt
Select a paper to view details